Recent Updates — SCNI
Scinai Immunotherapeutics Ltd. completed a financing transaction generating approximately $3.6 million in net proceeds, consisting of a private placement and the cash exercise of existing warrants. The company also announced a new contract development and manufacturing organization (CDMO) agreement with a U.S.-based biopharmaceutical customer, securing approximately $5.1 million in committed base service fees. This deal expanded Scinai's Committed Customer Orders to roughly $8.1 million as of October 20, 2026, up from $1.9 million at year-end 2025. Combined with the financing proceeds and expected customer payments, management estimates an operating runway extending to late 2027, potentially into mid-2028 if later project phases are activated. Scinai Immunotherapeutics Ltd. operates a contract development and manufacturing business alongside an immunology-focused therapeutic development platform.
Scinai Immunotherapeutics closed a previously announced private placement of 2,458,334 American Depositary Shares (ADSs) or pre-funded warrants, together with Series A-1 Warrants to purchase up to 3,687,501 ADSs. The company also completed the immediate exercise of Existing Warrants for 879,194 ADSs at a reduced price of $1.20 per ADS and issued additional New Warrants for 1,318,791 ADSs. Aggregate gross proceeds were approximately $4.0 million before fees. Net proceeds will advance customer programs, pursue CDMO contracts, and support the immunotherapy pipeline. The company estimates an operating runway to late 2027 based on current resources and expected collections. Scinai Immunotherapeutics is a biopharmaceutical company operating a contract development and manufacturing organization alongside an immunology-focused therapeutic development platform.
Scinai Immunotherapeutics entered into a Securities Purchase Agreement for the sale of 2,458,334 American Depositary Shares (ADSs) or pre-funded warrants, along with Series A-1 warrants to acquire up to 3,687,501 ADSs. The securities were sold at a combined price of $1.20 per ADS and accompanying warrants. Concurrently, the company executed a warrant inducement offering new Series A-1 warrants for 1,318,791 ADSs in exchange for the immediate cash exercise of existing April 2026 warrants at the same reduced $1.20 price. Gross proceeds from both transactions total approximately $4.0 million before fees and expenses, with closing expected around October 15, 2026. The company intends to use these funds to expand its contract development and manufacturing organization (CDMO) platform and advance its immunotherapy pipeline. Scinai Immunotherapeutics is a biopharmaceutical company operating a CDMO alongside an immunology-focused therapeutic development platform.
Scinai Immunotherapeutics announced a definitive development and clinical manufacturing agreement with a U.S.-based, Nasdaq-listed biopharmaceutical company. The deal includes approximately $5.1 million in committed base service fees for CMC development and clinical manufacturing of an investigational oncology product. Following this agreement, Scinai’s Committed Customer Orders reached approximately $7.6 million, up roughly 300% from $1.9 million at year-end 2025. The engagement supports activities in 2026 with clinical manufacturing planned for January 2027. Additionally, there is potential for uncommitted service fees valued at $5.85 million for late 2027 through early 2028. Scinai Immunotherapeutics Ltd. operates a contract development and manufacturing organization alongside an immunology-focused therapeutic development platform.
Scinai Immunotherapeutics Ltd. terminated its option and license arrangements for PC111 with PinCell S.r.l. after failing to reach an extension agreement before conditions expired on August 31, 2026. The company will refocus R&D resources on its NanoAb platform and CDMO business, citing the need to preserve capital in the absence of secured grant funding for PC111. Scinai is pursuing approximately €12 million in Polish grant financing for an intradermal IL-17 psoriasis program and has committed customer orders totaling $3.1 million as of August 16, 2026. The company aims to generate approximately $5 million in CDMO revenue for 2026 while advancing systemic IL-17 bispecific programs. Scinai Immunotherapeutics Ltd. is a biopharmaceutical company focused on innovative immunology therapies and operates a contract development and manufacturing organization.